================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: April 23, 2004
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------ -------------------
(Jurisdiction of (Commission (IRS Employer
Incorporation) File Number) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On April 23, 2004, QLT Inc. announced that Visudyne(R)
(verteporfin), currently the only treatment for some forms of "wet"
age-related macular degeneration (AMD), was reimbursed in Japan.
Visudyne was approved by the Japanese Ministry of Health, Labour and
Welfare in October 2003 for the "wet" form of AMD with all types of
subfoveal choroidal neovascularization.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- ------------
99.1 Press release dated April 23, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
----------------------
(Registrant)
Date April 23, 2004 /s/ Paul J. Hastings
--------------------------- -------------------------------------
(Signature)
President and Chief Executive Officer